AcelRX Pharmaceuticals is partnering with Brigham and Women's Hospital in Boston to study the perioperative use of DSUVIA in the analgesic regimen for spine surgery.
Three insights:
1. DSUVIA, a synthetic opioid tablet, received FDA approval in 2018.
2. The study will explore if DSUVIA is linked with a decrease in pain intensity in the recovery room, opioid consumption and side effects, number of IV fentanyl boluses and hospitalization costs.
3. Richard Urman, MD, associate professor of anesthesia and co-director of the center for perioperative research at BWH and Boston-based Harvard Medical School is leading the study.